Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03652272
Other study ID # STU00207507
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 8, 2019
Est. completion date September 27, 2021

Study information

Verified date April 2022
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is a well-documented need for effective interventions that can help patients understand and safely adhere to prescribed medications, particularly those with greater potential for harm if not taken correctly. The investigators will leverage health and consumer technologies with their EHR-based Medication Complete Communication (EMC2) Strategy to: 1) inform patients about medication risks and safe use, 2) promote provider education and counseling about prescribed drugs and 3) monitor patient adherence outside of visits. The EMC2 Strategy could be feasible, sustainable, and readily available to ambulatory care practices.


Description:

This is a 2-arm, multi-site, physician-randomized pragmatic trial to evaluate the impact and scalability of the EMC2 strategy to promote safe medication use and adherence. Treatment Arms and Duration: Usual Care. Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits. Intervention: EMC2 Strategy. In brief, there are several components to this strategy that will be embedded into the workflow via EHR/patient portal platforms, mostly automating their implementation. Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications: 1. Physician Medication Alert: If a prescribing physician attempts to place a new order or change to an existing study medication prescription, an EHR-generated alert will notify the provider that the medication requires patient counseling. Physicians can opt to ignore this alert. 2. Provider Counseling Support: Content from the 1-page, Med Guide Summary will appear on the screen, if selected by the provider, to orient and inform provider-patient discussion. 3. Automated Delivery of Med Guide + Summary: When patients leave an encounter, the medication order in Epic will automatically cue printing of both the 1-page, health literate Med Guide Summary for study medications and a full Med Guide, if applicable (latter is required by FDA for certain medications only, the former designed to enhance comprehension). 4. Follow-Up Portal Questionnaire: Within 1 week post-visit, patients will receive an automated email prompting them to log on to the patient portal. Patients' will be asked to fill out a short set of questions related to medication adherence, and other medication-related concerns (i.e. cost, side effects). If patients have not completed the questionnaire within 2 days, another email reminder will be sent. The information submitted back by the patient will be stored in the EHR. A second questionnaire will be sent 1 month later. The addition of the patient portal will provide opportunities to have ongoing communications with their clinic, access to regimen-specific medication information, and to provide a feedback loop informing healthcare providers of safety and adherence-related behaviors and concerns. 5. EHR Inbox Message to Clinic: The results of the patient portal questionnaire will be sent back to the EHR, populating an inbox message notifying the nurse/clinic staff and/or physician if a patient has a medication risk alert, detailing the nature of the issue (i.e. education needed, adherence problem, side effect concerns, etc.). The system will be flexible and allow the clinic to specify actions to be taken according to their workflow preferences; the default plan is that patient contact will be undertaken by nurses/clinic staff involved with care management. 6. Clinic Counseling: If a problem/concern is flagged during the review of the portal questionnaire, there will be an expectation for a clinic staff member to respond to the concern by calling the patient. A general orientation to staff at the clinic will provide guidance on how to perform brief counseling based on each specific clinic protocol. Number of Patients: While the expected sample size for this pragmatic study is 300, the investigators will recruit 330 patients (n=165 per site, the investigators anticipate 90% retention among the recruited sample by 3 months (n=297). The investigators therefore will over sample to accommodate some attrition.


Recruitment information / eligibility

Status Completed
Enrollment 301
Est. completion date September 27, 2021
Est. primary completion date September 27, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient is age 18 and older - Patient is English speaking - Patient is primarily responsible for administering their own medication - Patient must have received a new or changed prescription for a product(s), identified by Eli Lilly and the study team, within 7 days of recruitment - Patient must have access to the internet - Patient must have a patient portal account Exclusion Criteria: - Severe, uncorrectable vision - Severe hearing impairments - Severe cognitive impairment - No access to the internet or patient portal account Providers must meet the following eligibility criteria: • Resident, Attending Physician or Mid-level provider (NP, PA) working in the NMHC Endocrinology clinic or other study sites during study dates. *Adults unable to consent, individuals under the age of 18, and prisoners will be excluded from this research.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
EMC2
Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks Patients will receive a Medication Guide + Summary with their After Visit Summary Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study) Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols.

Locations

Country Name City State
United States Northwestern University Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Medication Specific Knowledge Patients will be asked about their medication's 1) indication, 2) risks or warnings, and 3) side effects. Correct answers will be tailored per medication and total scores will range from 0-100, reflecting the percent correct of possible points. Baseline-3 Months
Secondary Medication Adherence- Ask 12 The ASK-12 survey covers three adherence domains: inconvenience/forgetfulness, treatment beliefs and behavior. Scores range from 12-60, with higher scores translating to greater barriers to adherence. Baseline-3 Months
Secondary Medication Adherence - Proper Use Patients will be asked the last day they took their medication and how. A patient's proper timing (last day and # of times per day), dosing (number of pills per dose), and spacing between doses (for BID, TID medications only) will be coded as correct or incorrect. Patients will be classified as having properly used their medication if they correctly reported all components. Baseline- 3 Months
See also
  Status Clinical Trial Phase
Completed NCT04709640 - Pilot Study to Improve Medication Management in Older Adults N/A
Completed NCT03257579 - Myocardial Infarction Prescription Duration Adherence Study N/A
Completed NCT05376397 - Testing THRIVE 365 for Black Sexual Minority Men (On The Daily) N/A
Withdrawn NCT03427008 - A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients N/A
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Withdrawn NCT03292393 - Social Norms and Antihypertensive Medication Adherence N/A
Not yet recruiting NCT02876848 - A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study) N/A
Completed NCT02914730 - Insulin Dosing Practices in Persons With Diabetes on Multiple Daily Injections
Completed NCT02823795 - The Supporting Patient Activation in Transition to Home Intervention N/A
Completed NCT02797262 - Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System N/A
Completed NCT02066935 - Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil Multicenter Study
Completed NCT01934608 - The Effect of Synching Prescription Refills on Adherence N/A
Completed NCT01741311 - Secondary HIV Prevention and Adherence Among HIV-infected Drug Users N/A
Completed NCT01770314 - Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication. Phase 2
Recruiting NCT01105104 - An Enhanced Medication Monitoring Program Phase 1
Withdrawn NCT01430702 - Feasibility of Using a Telemedicine Medication Delivery Unit for Older Adults N/A
Completed NCT01859273 - Adherence Enhancement for Renal Transplant Patients N/A
Completed NCT01118208 - Blister Packaging Medication to Increase Treatment Adherence and Clinical Response N/A
Completed NCT00848224 - Improving Adherence to Pharmacological Treatment N/A
Completed NCT06034301 - Pill Bottle vs Reminder App N/A